Can-Fite BioPharma Ltd. (TLV:CANF)
1.000
0.00 (0.00%)
Oct 5, 2025, 12:01 PM IDT
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $202.00K USD in the half year ending June 30, 2025, a decrease of -48.47%. This brings the company's revenue in the last twelve months to $560.00K, down -16.04% year-over-year. In the year 2024, Can-Fite BioPharma had annual revenue of $674.00K, down -9.29%.
Revenue (ttm)
$560.00K
Revenue Growth
-16.04%
P/S Ratio
25.08
Revenue / Employee
$112.00K
Employees
5
Market Cap
47.32M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teva Pharmaceutical Industries | 56.02B |
Danel (Adir Yeoshua) | 2.84B |
Kamada | 571.15M |
Bait Bakfar | 106.25M |
BrainsWay | 155.27M |
SofWave Medical | 234.12M |
Ilex Medical | 927.57M |
Novolog (Pharm-Up 1966) | 2.04B |
Can-Fite BioPharma News
- 21 days ago - CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News - GuruFocus
- 22 days ago - Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment - GuruFocus
- 5 weeks ago - Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.2M - Seeking Alpha
- 5 weeks ago - Can-Fite Reports H1 2025 Financial Results and Clinical Update - GlobeNewsWire
- 2 months ago - Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone - GlobeNewsWire
- 2 months ago - Can-Fite Announces Up To $15.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia - GlobeNewsWire
- 2 months ago - Can-Fite BioPharma launches best-efforts offering of ADSs and warrants - Seeking Alpha